Luke J. Laffin
@ljlaffin
Followers
524
Following
2K
Statuses
191
Preventive Cardiologist, Co-Director Center for Blood Pressure Disorders, Medical Director of Cardiac Rehabilitation, @CleClinicMD
Cleveland, OH
Joined April 2009
RT @GarimaDahiyaMD: Excellent Article on Key Concepts in Machine Learning and Clinical Applications in the Cardiac Intensive Care Unit #CIC…
0
6
0
RT @RafeyNephro: George L Bakris Memorial Symposium on hypertension is around the corner ! It's a great opportunity to connect with the…
0
12
0
RT @CardiologyToday: 🗣️ In our 3-part #HealioExclusive, we discuss: 🔑The cardiometabolic consequences of obesity 🔑Emerging data on BP after…
0
2
0
RT @venumenon10: We have an opportunity for a staff position in the Clinical Section at the Cleveland Clinic. This section houses experts i…
0
11
0
1
0
1
Great to have you work with @CleClinicHVTI . Best of luck!
It was an honor to learn from Dr. Luke J. Laffin @ljlaffin , Co-Director of the Center for Blood Pressure Disorders at Cleveland Clinic, & his remarkable book Hypertension: A Companion to Braunwald’s Heart Disease (2024) Beautifully unravels the complexities of HTN #Hypertension
1
1
17
RT @CleClinicHVTI: Engaging @ClevelandClinic satellite symposium @MDVIP’s National Meeting this weekend, on current state-of-the-art practi…
0
4
0
RT @MelanieT_Editor: Congratulations to Dr. George Bakris @UChicagoMed Dr @ljlaffin @CleClinicMD and Dr. Matthew Sorrentino @UChicagoMed…
0
3
0
@djc795 @DrMarthaGulati @RawanAAmir Tirzepatide CVOT enrolling both - ( Bempedoic acid CVOT (CLEAR Outcomes) enrolled both Agree semaglutide not going to get label for primary prevention #cardsjc
2
0
5
@CardioNerdsJC Landmark trial. Not a perfect trial by any means, but demonstrated what many of us generally thought - weight reduction in patients with obesity is important and reduces adverse CV events. Now just need patients to be able to access these therapies. #cardsjc
0
0
3
@RawanAAmir Given increasing # of prescribers, obesity specialists, cardiologists, endocrinologists, internists, etc it is Important to consider these adverse events and know how to limit them. Slow dose titration etc. #cardsjc
1
2
4
@DrMarthaGulati @RawanAAmir Also tend to see lower HR among primary prevention pts, rather than secondary prevention pts (just takes longer for them to have events and need more of them) CLEAR Outcomes positive result was driven by primary prevention population #cardsjc
0
1
4
@MichaelAlbertMD @CardioNerdsJC Why do you think the CV death survival curves converge and then diverge Mike? I have my thoughts, but this was suprising #cardsjc
1
0
2
@DrMarthaGulati @RawanAAmir Lilly is with SURMOUNT MMO ( it's tirzepatide's CVOT. Not strictly primary prevention, but combined primary and secondary. #CardsJC
1
2
7
@DrEugeneYang @CardioNerdsJC That's a very important question - once it gets on the FDA label, they'll hopefully be more uptake - but there will be the usual insurance barriers (much like when PCSK9i were introduced.) #cardsjc
0
0
2